Oxcarbazepine
Brand names: Trileptal · Active ingredient: Oxcarbazepine
In short: Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients age
What is Oxcarbazepine used for?
Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.
Oxcarbazepine dosage
Initiate oxcarbazepine oral suspension with a dose of 600 mg/day, given twice a day. If clinically indicated, the dose may be increased by a maximum of 600 mg/day at approximately weekly intervals; the maximum recommended daily dose is 1200 mg/day. Daily doses above 1200 mg/day show somewhat greater effectiveness in controlled trials, but most patients were not able to tolerate the 2400 mg/day dose, primarily because of central nervous (CNS) effects.
Dosage adjustment is recommended with concomitant use of strong CYP3A4 enzyme inducers or UDP-glucuronosyltransferases (UGT) inducers, which include certain antiepileptic drugs (AEDs) .
Patients receiving concomitant AEDs may be converted to monotherapy by initiating treatment with oxcarbazepine oral suspension at 600 mg/day (given in a twice a day regimen) while simultaneously initiating the reduction of the dose of the concomitant AEDs. The concomitant AEDs should be completely withdrawn over 3 to 6 weeks, while the maximum dose of oxcarbazepine oral suspension should be reached in about 2 to 4 weeks. Oxcarbazepine oral suspension may be increased as clinically indicated by a maximum increment of 600 mg/day at approximately weekly intervals to achieve the maximum recommended daily dose of 2400 mg/day. A daily dose of 1200 mg/day has been shown in one study to be effective in patients in whom monotherapy has been initiated with oxcarbazepine oral suspension. Patients should be observed closely during this transition phase.
Patients not currently being treated with AEDs may have monotherapy initiated with oxcarbazepine oral suspension. In these patients, initiate oxcarbazepine oral suspension at a dose of 600 mg/day (given twice a day); the dose should be increased by 300 mg/day every third day to a dose of 1200 mg/day. Controlled trials in these patients examined the effectiveness of a 1200 mg/day dose; a dose of 2400 mg/day has been shown to be effective in patients converted from other AEDs to oxcarbazepine oral suspension monotherapy .
In pediatric patients aged 4 to 16 years, initiate oxcarbazepine oral suspension at a daily dose of 8 to 10 mg/kg generally not to exceed 600 mg/day, given twice a day. The target maintenance dose of oxcarbazepine oral suspension should be achieved over 2 weeks, and is dependent upon patient weight, according to the following chart:
20 to 29 kg – 900 mg/day
29.1 to 39 kg – 1200 mg/day
39 kg – 1800 mg/day
In the clinical trial, in which the intention was to reach these target doses, the median daily dose was 31 mg/kg with a range of 6 to 51 mg/kg.
In pediatric patients aged 2 to less than 4 years, initiate oxcarbazepine oral suspension at a daily dose of 8 to 10 mg/kg generally not to exceed 600 mg/day, given twice a day. …
How to take Oxcarbazepine — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Administration Information
Counsel patients that oxcarbazepine oral suspension may be taken with or without food.
For oxcarbazepine oral suspension, advise patients to shake the bottle well and prepare the dose immediately afterwards using the oral dosing syringe supplied. Inform patients that oxcarbazepine oral suspension can be mixed in a small glass of water just prior to administration or, alternatively, may be swallowed directly from the syringe. Instruct patients to discard any unused oxcarbazepine oral suspension after 7 weeks of first opening the bottle .
Hyponatremia
Advise patients that oxcarbazepine oral suspension may reduce the serum sodium concentrations especially if they are taking other medications that can lower sodium. Instruct patients to report symptoms of low sodium like nausea, tiredness, lack of energy, confusion, and more frequent or more severe seizures .
Anaphylactic Reactions and Angioedema
Anaphylactic reactions and angioedema may occur during treatment with oxcarbazepine oral suspension. …
Warnings & precautions
Do not take this medicine if: Oxcarbazepine oral suspension is contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate .
Clinically significant hyponatremia (sodium less than 125 mmol/L) can develop during oxcarbazepine oral suspension use. In the 14 controlled epilepsy studies, 2.5% of oxcarbazepine oral suspension-treated patients (38/1,524) had a sodium of less than 125 mmol/L at some point during treatment, compared to no such patients assigned placebo or active control (carbamazepine and phenobarbital for adjunctive and monotherapy substitution studies, and phenytoin and valproate for the monotherapy initiation studies). Clinically significant hyponatremia generally occurred during the first 3 months of treatment with oxcarbazepine oral suspension, although there were patients who first developed a serum sodium less than 125 mmol/L more than 1 year after initiation of therapy. Most patients who developed hyponatremia were asymptomatic, but patients in the clinical trials were frequently monitored and some had their oxcarbazepine oral suspension dose reduced, discontinued, or had their fluid intake restricted for hyponatremia. Whether or not these maneuvers prevented the occurrence of more severe events is unknown. Cases of symptomatic hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH) have been reported during postmarketing use. In clinical trials, patients whose treatment with oxcarbazepine oral suspension was discontinued due to hyponatremia generally experienced normalization of serum sodium within a few days without additional treatment. …
Oxcarbazepine side effects
The following serious adverse reactions are described below and elsewhere in the labeling:
Hyponatremia
Anaphylactic Reactions and Angioedema
Cross Hypersensitivity Reaction to Carbamazepine
Serious Dermatological Reactions
Suicidal Behavior and Ideation
Cognitive/Neuropsychiatric Adverse Reactions
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multi-Organ Hypersensitivity
Hematologic Events
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Most Common Adverse Reactions in All Clinical Studies
Adjunctive Therapy/Monotherapy in Adults Previously Treated With Other AEDs
The most common (≥10% more than placebo for adjunctive or low dose for monotherapy) adverse reactions with oxcarbazepine oral suspension: dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, headache, nystagmus tremor, and abnormal gait.
Approximately 23% of these 1,537 adult patients discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were: dizziness (6.4%), diplopia (5.9%), ataxia (5.2%), vomiting (5.1%), nausea (4.9%), somnolence (3.8%), headache (2.9%), fatigue (2.1%), abnormal vision (2.1%), tremor (1.8%), abnormal gait (1.7%), rash (1.4%), and hyponatremia (1.0%). …
Drug interactions
Phenytoin levels have been shown to increase with concomitant use of oxcarbazepine oral suspension at doses greater than 1200 mg/day . Therefore, it is recommended that the plasma levels of phenytoin be monitored during the period of oxcarbazepine oral suspension titration and dosage modification. A decrease in the dose of phenytoin may be required.
Strong inducers of cytochrome P450 enzymes and/or inducers of UGT (e.g., rifampin, carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma/serum levels of MHD, the active metabolite of oxcarbazepine oral suspension (25% to 49%) . If oxcarbazepine oral suspension and strong CYP3A4 inducers, or UGT inducers are administered concurrently, it is recommended that the plasma levels of MHD be monitored during the period of oxcarbazepine oral suspension titration. Dose adjustment of oxcarbazepine oral suspension may be required after initiation, dosage modification, or discontinuation of such inducers.
Concurrent use of oxcarbazepine oral suspension with hormonal contraceptives may render these contraceptives less effective . Studies with other oral or implant contraceptives have not been conducted.
About this medicine
Oxcarbazepine oral suspension, USP is an antiepileptic drug available as a 300 mg/5 mL (60 mg/mL) oral suspension. Oxcarbazepine is 10,11-Dihydro-10-oxo- 5H-dibenz[b,f]azepine-5-carboxamide, and its structural formula is:
Oxcarbazepine, USP is light orange to creamish white or off-white powder. It is slightly soluble in chloroform, dichloromethane, acetone, and methanol and practically insoluble in ethanol, ether and water. Its molecular weight is 252.27.
Oxcarbazepine oral suspension, USP contains the following inactive ingredients: methyl paraben, propyl paraben, saccharin sodium dihydrate,polyoxyl stearate, malic acid, non-crystalline sorbitol, propylene glycol, microcrystalline cellulose, carboxy methyl cellulose sodium, hydroxyethyl cellulose, cherry flavour and purified water.
FDA approved dissolution test specifications differ fromUSP.
How it works: The pharmacological activity of oxcarbazepine oral suspension is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine . …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3f36f519-c30c-4929-afa0-9844dc531e3f. Read the full official label on DailyMed.
Related medicines
Gabapentin Lamotrigine Pregabalin Topiramate Levetiracetam Carbamazepine Ciclopirox Clorazepate